Amgen Inc., established in 1980 in Thousand Oaks, California, is a leading biotechnology company with around 24,000 employees globally. Known for pioneering recombinant DNA technology, Amgen’s key products include Enbrel for rheumatoid arthritis, Neulasta for infection prevention in chemotherapy patients, and Prolia for osteoporosis. The recent FDA approval of IMDELLTRA™, a bispecific T-cell engager for treating extensive-stage small cell lung cancer, and positive Phase 3 results for UPLIZNA® in treating Immunoglobulin G4-related disease highlight Amgen’s ongoing innovation in biopharmaceuticals.